TriSalus Life Sciences Exceeds 2025 Revenue Guidance with 53% Growth, Narrows Q4 Loss
summarizeSummary
TriSalus Life Sciences reported strong fourth quarter and full-year 2025 financial results, exceeding its 2025 revenue guidance. The company generated $13.2 million in Q4 revenue, a 60% year-over-year increase, and $45.2 million for the full year, representing a 53% increase, surpassing its 50% guidance. Adjusted EBITDA loss significantly narrowed to $0.9 million in Q4 2025 from $5.7 million in the prior year. The company also reaffirmed its 2026 revenue guidance of $60-62 million, supported by the $46 million in gross proceeds from a recent public offering, which was previously disclosed in late February SEC filings. This strong performance and strengthened balance sheet provide capital for continued growth and commercial expansion, indicating positive momentum for the company.
At the time of this announcement, TLSI was trading at $4.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.3M. The 52-week trading range was $3.42 to $7.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.